Skip to main content Skip to navigation
Hamburger Menu
Search icon
Country Selector Country Selector
Japan (Japanese)
Profile Icon Profile Icon
Sign-in/Register UserName
Products

Solutions

Discover & Learn

Resources & Tools

Support

Search icon Search icon
Close Menu
      Alert Icon
      BV750 Mouse Anti-Human CD7
      製品詳細
      Down Arrow Up Arrow


      BD OptiBuild™
      LEU-9; T-cell leukemia antigen; T-cell surface antigen Leu-9
      Human (Tested in Development)
      Mouse BALB/c IgG2a, κ
      T-acute lymphoblastic leukemia cells
      Flow cytometry (Qualified)
      0.2 mg/ml
      II T 31; III T 563; V NK12; VI T 6T-R7, T 6T-CD7.2, BP 494, BP 543
      924
      Aqueous buffered solution containing ≤0.09% sodium azide.
      RUO


      Preparation and Storage

      Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
      詳細を表示 blue down arrow 表示項目を減らす blue up arrow

      推奨アッセイ手順

      BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation).  When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells.   However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls.  It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.

      For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime BD Horizon Brilliant dyes are used in a multicolor flow cytometry panel.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. When BD Horizon Brilliant Stain Buffer is used in in the multicolor panel, it should also be used in the corresponding compensation controls for all dyes to achieve the most accurate compensation. For the most accurate compensation, compensation controls created with either cells or beads should be exposed to BD Horizon Brilliant Stain Buffer for the same length of time as the corresponding multicolor panel. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).

      詳細を表示 blue down arrow 表示項目を減らす blue up arrow

      Product Notices

      1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
      2. Researchers should determine the optimal concentration of this reagent for their individual applications.
      3. An isotype control should be used at the same concentration as the antibody of interest.
      4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
      5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
      6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
      7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
      8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
      9. BD Horizon Brilliant™ Violet 750 is covered by one or more of the following US patents: 8,158,444; 8,802,450; 8,575,303; 8,455,613; 8,227,187; 8,841,072; 8,110,673.
      10. Human donor specific background has been observed in relation to the presence of anti-polyethylene glycol (PEG) antibodies, developed as a result of certain vaccines containing PEG, including some COVID-19 vaccines. We recommend use of BD Horizon Brilliant™ Stain Buffer in your experiments to help mitigate potential background. For more information visit https://www.bdbiosciences.com/en-us/support/product-notices.
      詳細を表示 blue down arrow 表示項目を減らす blue up arrow
      753766 Rev. 1
      抗体の詳細
      Down Arrow Up Arrow
      4H9

      The 4H9 (Leu-9) monoclonal antibody specifically recognizes human CD7 which is also known as T-cell leukemia antigen, T-cell surface antigen Leu-9, and  LEU-9. CD7 is a ~40 kDa type I transmembrane glycoprotein that has an extracellular region with an N-terminal IgV-like domain followed by an extended O-glycosylated stalk region, a transmembrane region and cytoplasmic tail. The CD7 antigen is expressed throughout T-lymphocyte differentiation. It is present on 85% to 90% of peripheral blood T lymphocytes. In normal individuals, CD7 is expressed on all CD8+ lymphocytes, approximately 90% of CD4+ lymphocytes, and most NK cells. CD7 is weakly expressed on monocytes but not on granulocytes or B lymphocytes. It is expressed on hematopoietic progenitors and 50% of thymocytes. In leukemias, the CD7 antigen is present on the majority of T-lymphoid lineages. CD7 may function in cellular adhesion and play a role in interactions between T cells as well as T cells and B cells.

      753766 Rev. 1
      フォーマットの詳細
      Down Arrow Up Arrow
      BV750
      The BD Horizon Brilliant Violet™ 750 (BV750) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 409-nm and an acceptor dye with an emission maximum (Em Max) at 754-nm. BV750, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 750-nm (e.g., a 750/30 nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
      altImg
      BV750
      Violet 405 nm
      409 nm
      754 nm
      753766 Rev.1
      引用＆参考文献
      Down Arrow Up Arrow
      View product citations for antibody "753766" on CiteAb

      Development References (9)

      1. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma.. Blood. 1986; 68(1):1-31. (Clone-specific). View Reference
      2. Link M, Warnke R, Finlay J, et al. A single monoclonal antibody identifies T-cell lineage of childhood lymphoid malignancies.. Blood. 1983; 62(4):722-8. (Immunogen: Flow cytometry). View Reference
      3. Palker TJ, Scearce RM, Hensley LL, Ho W, Haynes BF. Comparison of the CD7 (3A1) group of T cell workshop antibodies. In: Reinherz EL, Haynes BF, Nadler LM, Bernstein ID, ed. Leukocyte Typing II. Human T Lymphocytes. New York, NY: Springer-Verlag; 1986:303-313.
      4. Picker LJ, Weiss LM, Medeiros LJ, Wood GS, Warnke RA. Immunophenotypic criteria for the diagnosis of non-Hodgkin's lymphoma.. Am J Pathol. 1987; 128(1):181-201. (Clone-specific: Immunohistochemistry). View Reference
      5. Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994; 152(2):517-526. (Clone-specific: Flow cytometry). View Reference
      6. Weiss LM, Crabtree GS, Rouse RV, Warnke RA. Morphologic and immunologic characterization of 50 peripheral T-cell lymphomas.. Am J Pathol. 1985; 118(2):316-24. (Clone-specific: Immunohistochemistry). View Reference
      7. Weiss LM, Wood GS, Warnke RA. Immunophenotypic differences between dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides.. Am J Pathol. 1985; 120(2):179-85. (Clone-specific: Immunohistochemistry). View Reference
      8. Wood GS, Abel EA, Hoppe RT, Warnke RA. Leu-8 and Leu-9 antigen phenotypes: immunologic criteria for the distinction of mycosis fungoides from cutaneous inflammation.. J Am Acad Dermatol. 1986; 14(6):1006-13. (Clone-specific: Immunohistochemistry). View Reference
      9. Zola H, Swart B, Nicholson I, Voss E. CD7. In: Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007:52.
      すべて表示する (9) 表示項目を減らす
      753766 Rev. 1

      Please refer to Support Documents for Quality Certificates


      Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


      Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

      For Research Use Only. Not for use in diagnostic or therapeutic procedures.